IL6R and rheumatoid arthritis: The human anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) in patients who respond inadequately or are intolerant to therapy with disease-modifying antirheumatic drugs (DMARDs).